Limited ability of posaconazole to cure both acute and chronic Trypanosoma cruzi infections revealed by highly sensitive in vivo imaging

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 8, 2015, Pages 4653-4661

  Francisco, Amanda Fortes ^a   Lewis, Michael D ^a,c   Jayawardhana, Shiromani ^a   Taylor, Martin C ^a   Chatelain, Eric ^b   Kelly, John M ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b Drugs for Neglected Diseases Initiative   (Switzerland)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE; CYCLOPHOSPHAMIDE; POSACONAZOLE; ANTIFUNGAL AGENT; ANTITRYPANOSOMAL AGENT; NITROIMIDAZOLE DERIVATIVE; TRIAZOLE DERIVATIVE;

ACUTE TRYPANOSOMA CRUZI INFECTION; ADIPOSE TISSUE; ANIMAL TISSUE; ANTIMICROBIAL THERAPY; ARTICLE; BIOLUMINESCENCE; CHAGAS DISEASE; CHRONIC TRYPANOSOMA CRUZI INFECTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; EX VIVO STUDY; FEMALE; IN VIVO STUDY; LIMIT OF DETECTION; MOUSE; NONHUMAN; PARASITE LOAD; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELAPSE; SPLENOMEGALY; TREATMENT DURATION; ANIMAL; BAGG ALBINO MOUSE; CHRONIC DISEASE; DISEASE MODEL; DRUG EFFECTS; PARASITOLOGY; SCID MOUSE; TRYPANOSOMA CRUZI;

ANIMALS; ANTIFUNGAL AGENTS; CHAGAS DISEASE; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; FEMALE; MICE; MICE, INBRED BALB C; MICE, SCID; NITROIMIDAZOLES; TRIAZOLES; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 84939817804     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00520-15     Document Type: Article

References (32)

1. Moncayo A, Silveira AC. 2009. Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem Inst Oswaldo Cruz 104:17-30.
2. Rassi A, Jr, Rassi A, Marin-Neto JA. 2010. Chagas disease. Lancet 375:1388-1402. http://dx.doi.org/10.1016/S0140-6736(10)60061-X.
3. Marin-Neto JA, Rassi A, Jr, Morillo CA, Avezum A, Connolly SJ, Sosa-Estani S, Rosas F, Yusuf S. 2008. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J 156:37-43. http://dx.doi.org/10.1016/j.ahj.2008.04.001.
4. Wilkinson SR, Kelly JM. 2009. Trypanocidal drugs: mechanisms, resistance and new targets. Expert Rev Mol Med 11:e31. http://dx.doi.org/10.1017/S1462399409001252.
5. Patterson S, Wyllie S. 2014. Nitro drugs for the treatment of trypanosomatids diseases: past, present, and future prospects. Trends Parasitol 30: 289-298. http://dx.doi.org/10.1016/j.pt.2014.04.003.
6. Castro JA, de Mecca MM, Bartel LC. 2006. Toxic side effects of drugs used to treat Chagas disease (American trypanosomiasis). Hum Exp Toxicol 25:471-479. http://dx.doi.org/10.1191/0960327106het653oa.
7. Le Loup G, Pialoux G, Lescure FX. 2011. Update in treatment of Chagas disease. Curr Opin Infect Dis 24:428-434.
8. Wilkinson SR, Taylor MC, Horn D, Kelly JM, Cheeseman I. 2008. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci U S A 105:5022-5027. http://dx.doi.org/10.1073/pnas.0711014105.
9. Hall BS, Wilkinson SR. 2012. Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation. Antimicrob Agents Chemother 56:115-123. http://dx.doi.org/10.1128/AAC.05135-11.
10. Hall BS, Bot C, Wilkinson SR. 2011. Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. J Biol Chem 286:13088-13095. http://dx.doi.org/10.1074/jbc.M111.230847.
11. Trochine A, Creek DJ, Faral-Tello P, Barrett MP, Robello C. 2014. Benznidazole biotransformation and multiple targets in Trypanosoma cruzi revealed by metabolomics. PLoS Negl Trop Dis 8:e2844. http://dx.doi.org/10.1371/journal.pntd.0002844.
12. Mejia AM, Hall BS, Taylor MC, Gómez-Palacio A, Wilkinson SR, Triana-Chávez O, Kelly JM. 2012. Benznidazole-resistance in Trypanosoma cruzi is a readily acquired trait that can arise independently in a single population. J Infect Dis 206:220-228. http://dx.doi.org/10.1093/infdis/jis331.
13. Campos MCO, Leon LL, Taylor MC, Kelly JM. 2014. Benznidazole-resistance in Trypanosoma cruzi: evidence that distinct mechanisms can act in concert. Mol Biochem Parasitol 193:17-19. http://dx.doi.org/10.1016/j.molbiopara.2014.01.002.
14. Urbina JA. 2009. Ergosterol biosynthesis and drug development for Chagas disease. Mem Inst Oswaldo Cruz 104(Suppl 1):S311-S318.
15. Lepesheva GI, Villalta F, Waterman MR. 2012. Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51). Adv Parasitol 75:65-87. http://dx.doi.org/10.1016/B978-0-12-385863-4.00004-6.
16. Pinazo MJ, Espinosa G, Gállego M, López-Chejade PL, Urbina JA, Gascón J. 2010. Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. Am J Trop Med Hyg 82:583-587. http://dx.doi.org/10.4269/ajtmh.2010.09-0620.
17. Lepesheva GI, Hargrove TY, Anderson S, Kleshchenko Y, Furtak V, Wawrzak Z, Villalta F, Waterman MR. 2010. Structural insights into inhibition of sterol 14α-demethylase in the human pathogen Trypanosoma cruzi. J Biol Chem 285:25582-25590. http://dx.doi.org/10.1074/jbc.M110.133215.
18. Urbina JA, Payares G, Contreras LM, Liendo A, Sanoja C, Molina J, Piras M, Piras R, Perez N, Wincker P, Loebenberg D. 1998. Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob Agents Chemother 42:1771-1777.
19. Diniz Lde F, Urbina JA, de Andrade IM, Mazzeti AL, Martins TA, Caldas IS, Talvani A, Ribeiro I, Bahia MT. 2013. Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments. PLoS Negl Trop Dis 7:e2367. http://dx.doi.org/10.1371/journal.pntd.0002367.
20. Bustamante JM, Craft JM, Crowe BD, Ketchie SA, Tarleton RL. 2014. New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice. J Infect Dis 209:150-162. http://dx.doi.org/10.1093/infdis/jit420.
21. Molina I, Gómez i Prat J, Salvador F, Treviño B, Sulleiro E, Serre N, Pou D, Roure S, Cabezos J, Valerio L, Blanco-Grau A, Sánchez-Montalvá A, Vidal X, Pahissa A. 2014. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. N Engl J Med 370:1899-1908. http://dx.doi.org/10.1056/NEJMoa1313122.
22. Moraes CB, Giardini MA, Kim H, Franco CH, Araujo-Junior AM, Schenkman S, Chatelain E, Freitas-Junior LH. 2014. Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development. Sci Rep 4:4703. http://dx.doi.org/10.1038/srep04703.
23. Branchini BR, Ablamsky DM, Davis AL, Southworth TL, Butler B, Fan F, Jathoul AP, Pule MA. 2010. Red-emitting luciferases for bioluminescence reporter and imaging applications. Anal Biochem 396:290-297. http://dx.doi.org/10.1016/j.ab.2009.09.009.
24. Lewis MD, Fortes Francisco A, Taylor MC, Burrell-Saward H, McLatchie AP, Miles MA, Kelly JM. 2014. Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection. Cell Microbiol 16:1285-1300. http://dx.doi.org/10.1111/cmi.12297.
25. Cummings KL, Tarleton RL. 2003. Rapid quantitation of Trypanosoma cruzi in host tissue by real-time PCR. Mol Biochem Parasitol 129:53-59. http://dx.doi.org/10.1016/S0166-6851(03)00093-8.
26. Cencig S, Coltel N, Truyens C, Carlier Y. 2011. Parasitic loads in tissues of mice infected with Trypanosoma cruzi and treated with AmBisome. PLoS Negl Trop Dis 5:e1216. http://dx.doi.org/10.1371/journal.pntd.0001216.
27. Olivieri BP, Molina JT, de Castro SL, Pereira MC, Calvet CM, Urbina JA, Araújo-Jorge TC. 2010. A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease. Int J Antimicrob Agents 36:79-83. http://dx.doi.org/10.1016/j.ijantimicag.2010.03.006.
28. Cencig S, Coltel N, Truyens C, Carlier Y. 2012. Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome® in mice infected with Trypanosoma cruzi strains. Int J Antimicrob Agents 40:527-532. http://dx.doi.org/10.1016/j.ijantimicag.2012.08.002.
29. Dos Santos FM, Caldas S, de Assis Cáu SB, Crepalde GP, de Lana M, Machado-Coelho GL, Veloso VM, Bahia MT. 2008. Trypanosoma cruzi: induction of benznidazole resistance in vivo and its modulation by in vitro culturing and mice infection. Exp Parasitol 120:385-390. http://dx.doi.org/10.1016/j.exppara.2008.09.007.
30. Li Y, Theuretzbacher U, Clancy CJ, Nguyen MH, Derendorf H. 2010. Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet 49:379-396. http://dx.doi.org/10.2165/11319340-000000000-00000.
31. Ferreira AV, Segatto M, Menezes Z, Macedo AM, Gelape C, de Oliveira Andrade L, Nagajyothi F, Scherer PE, Teixeira MM, Tanowitz HB. 2011. Evidence for Trypanosoma cruzi in adipose tissue in human chronic Chagas disease. Microbes Infect 13:1002-1005. http://dx.doi.org/10.1016/j.micinf.2011.06.002.
32. Nagajyothi F, Machado FS, Burleigh BA, Jelicks LA, Scherer PE, Mukherjee S, Lisanti MP, Weiss LM, Garg NJ, Tanowitz HB. 2012. Mechanisms of Trypanosoma cruzi persistence in Chagas disease. Cell Microbiol 14:634-643. http://dx.doi.org/10.1111/j.1462-5822.2012.01764.x.